Review: inducer of cytokines in vivo: overview of field and romurtide experience.
We have reported that the bacterial cell-wall skeletons, such as mycobacteria, nocardia, corynebacteria, propionibacteria and listeria, had potent adjuvant activity on immune responses. It was reported that N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) was the minimum structural requirement of adjuvant activity of the bacterial cell-wall skeleton and a variety of MDP derivatives and related compounds were synthesized. Among the synthetic MDP derivatives, we have selected MDP-Lys(L18)(romurtide) as the immunostimulant, by using experimental models for non-specific host resistance against Escherichia coli in mice. Romurtide was shown to have host-stimulating activity against bacterial, fungal and viral infections, cytokine producing activity and the capacity to increase the number of leukocytes and platelets in experimental models. It was also shown that the clinical effectiveness of romurtide on the restoration of the number of leukocytes and platelets of cancer patients treated with chemotherapy or radiation therapy. The mechanism of action of romurtide is discussed.
Azuma
I
I
Institute of Immunological Science, Hokkaido University, Sapporo, Japan.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D016207:Cytokines / Q000096:biosynthesis; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007239:Infections / Q000276:immunology*; D007970:Leukopenia / Q000150:complications / Q000188:drug therapy*; D051379:Mice; D009369:Neoplasms / Q000150:complications*
D000276:Adjuvants, Immunologic; D016207:Cytokines; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C036866:romurtide